Core Insights - The stock price of Haitai Newlight closed at 35.19 yuan, up 1.85%, with a rolling PE ratio of 29.56, marking a 20-day low, and a total market capitalization of 4.244 billion yuan [1] - In the medical device industry, the average PE ratio is 48.90, with a median of 36.41, placing Haitai Newlight at the 66th position [1] - As of the first quarter of 2025, 26 institutions hold shares in Haitai Newlight, including 22 funds, 3 others, and 1 social security fund, with a total holding of 57.068 million shares valued at 2.145 billion yuan [1] Company Overview - Qingdao Haitai Newlight Technology Co., Ltd. specializes in the research, development, production, sales, and service of medical endoscope instruments and optical products [1] - The main products include high-definition fluorescence endoscope instruments, high-definition white light endoscope instruments, endoscope accessories, and endoscope maintenance services [1] - The company has achieved significant technological advancements in the field of medical endoscope instruments and optical products, holding 37 domestic and international invention patents and undertaking several key national and provincial science and technology projects [1] Financial Performance - For the first quarter of 2025, the company reported revenue of 147 million yuan, a year-on-year increase of 24.86%, and a net profit of 46.6887 million yuan, up 21.45%, with a gross profit margin of 64.98% [1]

证券代码：688677 证券简称：海泰新光 公告编号：2025-028 公司于 2025 年 3 月 3 日召开第四届董事会第三次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》（以下简称"本次回购方案"），同意 公司以自有资金及回购专项贷款资金通过上海证券交易所交易系统以集中竞价交 易方式回购公司已发行的部分人民币普通股股票。回购的股份将在未来适宜时机 全部用于员工持股计划或股权激励，回购价格不超过 59 元/股（含），回购资金总 额不低于人民币 5,000 万元（含），不超过人民币 10,000 万元（含），回购期限自 公司董事会审议通过本次回购方案之日起 12 个月内。具体内容详见公司于 2025 年 3 月 5 日在上海证券交易所网站（www.sse.com.cn）上披露的《青岛海泰新光 科技股份有限公司关于以集中竞价交易方式回购股份的预案》（公告编号： 2025-006）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应当在每个月的前 3 个交易日 内公告截至上月末的回购进展情况，现将公 ...

特此公告。 青岛海泰新光科技股份有限公司董事会 青岛海泰新光科技股份有限公司 关于参加 2025 年青岛辖区上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，青岛海泰新光科技股份有限公司（以下 简称"公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市全景网 络有限公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）或关注微信公众号（名称：全景财经）或下载全景路演 APP,参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00-17:00。 届时公司高管将以在线交流形式就公司治理、发展战略、经营状况等投资者关注 的问题与投资者进行沟通与交流，欢迎广大投资者踊跃参与。 证券代码：688677 证券简称：海泰新光 公告编号：2025-027 2025 年 5 月 7 日 1 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][7]. Core Insights - The company experienced a revenue decline of 6% in 2024, with total revenue of 443 million yuan and a net profit of 135 million yuan, down 7% year-on-year. This was attributed to delayed recovery in core customer demand [7]. - In Q1 2025, the company reported a revenue of 147 million yuan, reflecting a year-on-year growth of 24.9%, and a net profit of 47 million yuan, up 21.5% year-on-year, indicating a recovery in performance [7]. - The company is entering a product harvest phase with several new medical endoscope products launched or set to launch in both domestic and international markets, which is expected to drive future growth [7]. Financial Data and Profit Forecast - The company’s total revenue is projected to grow from 565 million yuan in 2025 to 791 million yuan in 2027, with corresponding net profits expected to rise from 183 million yuan to 276 million yuan [6][9]. - The gross margin is expected to remain stable at around 64.5% over the forecast period, with a return on equity (ROE) projected to increase from 12.5% in 2025 to 15.5% in 2027 [6]. - The price-to-earnings (PE) ratio is forecasted to decrease from 23 in 2025 to 15 in 2027, indicating potential undervaluation compared to industry peers [7].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][10] Core Views - The company's performance in 2024 is under short-term pressure, but a turning point is expected in Q1 2025 [1][9] - The company has successfully launched new products in the medical endoscope sector, with steady growth anticipated in 2024 [3][9] - The company’s revenue for 2024 is projected at 4.43 billion yuan, a decrease of 5.90% year-on-year, while the net profit is expected to be 1.35 billion yuan, down 7.11% [9][10] Financial Summary - Total revenue (million yuan): 2023A: 470.60, 2024A: 442.83, 2025E: 542.15, 2026E: 639.44, 2027E: 755.09 [1] - Year-on-year growth rates for total revenue: 2024A: -5.90%, 2025E: 22.43%, 2026E: 17.95%, 2027E: 18.09% [1] - Net profit attributable to the parent company (million yuan): 2023A: 145.71, 2024A: 135.35, 2025E: 175.31, 2026E: 213.04, 2027E: 262.06 [1] - Year-on-year growth rates for net profit: 2024A: -7.11%, 2025E: 29.52%, 2026E: 21.53%, 2027E: 23.01% [1] - Latest diluted EPS (yuan/share): 2023A: 1.21, 2024A: 1.12, 2025E: 1.45, 2026E: 1.77, 2027E: 2.17 [1] - Current P/E ratios: 2024A: 30.79, 2025E: 23.77, 2026E: 19.56, 2027E: 15.90 [1][10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][10] Core Views - The company's performance in 2024 is under short-term pressure, but a turning point is expected in Q1 2025 [9][10] - The company has successfully launched new products in the medical endoscope sector, with steady growth anticipated in 2024 [3][9] - The company is adapting to trade policy changes through its overseas subsidiaries and new product collaborations [9][10] Financial Performance Summary - In 2024, the company achieved total revenue of 442.83 million yuan, a decrease of 5.90% year-on-year, and a net profit attributable to shareholders of 135.35 million yuan, down 7.11% [9] - For Q1 2025, the company reported revenue of 147 million yuan, an increase of 24.86%, and a net profit of 47 million yuan, up 21.45% [9] - The company's main business revenue accounted for 99.49% of total revenue in 2024, with the medical endoscope segment contributing 345.16 million yuan, a decline of 7.04% [9] Earnings Forecast and Valuation - The forecast for net profit attributable to shareholders has been adjusted for 2025 and 2026 to 175.31 million yuan and 213.04 million yuan, respectively [10] - The expected P/E ratios for the current market value are 24x for 2025, 20x for 2026, and 16x for 2027 [10] - The company is projected to achieve a net profit of 262.06 million yuan in 2027, with a corresponding EPS of 2.17 yuan [1][10]

Core Viewpoint - The company reported a decline in annual revenue and net profit for 2024, but showed significant quarter-on-quarter recovery in Q4 2024 and Q1 2025, driven by recovering customer demand and overseas orders [1][2]. Financial Performance - In 2024, the company achieved revenue of 443 million yuan (YoY -5.90%) and a net profit of 135 million yuan (YoY -7.11%), with a non-net profit of 129 million yuan (YoY -5.26%) [1]. - For Q4 2024, revenue was 124 million yuan (YoY +31.59%), net profit was 38 million yuan (YoY +37.92%), and non-net profit was 40 million yuan (YoY +57.44%) [1]. - In Q1 2025, revenue reached 147 million yuan (YoY +24.86%), net profit was 47 million yuan (YoY +21.45%), and non-net profit was 46 million yuan (YoY +26.89%) [1]. Business Segments - The medical endoscope business in 2024 generated revenue of 345 million yuan (YoY -7%), influenced by customer order demand and product structure adjustments [2]. - The optical products segment reported revenue of 95 million yuan (YoY -1.8%) [2]. - The company is launching new products, including a 4mm hysteroscope and various endoscopes, which are expected to enhance overseas business growth [2]. Strategic Initiatives - The company is enhancing its overseas production capabilities, with successful certifications for its U.S. subsidiary and the establishment of production capacity in Thailand [3]. - Collaboration with U.S. clients on next-generation systems is expanding the product range into various medical fields [3]. Profit Forecast - Revenue projections for 2025-2027 are 552 million yuan, 676 million yuan, and 812 million yuan, with respective growth rates of 24.64%, 22.54%, and 20.00% [3]. - Net profit forecasts for the same period are 187 million yuan, 234 million yuan, and 283 million yuan, with growth rates of 38.00%, 25.50%, and 20.92% [3].

2025 年 04 月 29 日 公司点评 买入/维持 海泰新光(688677) 昨收盘:34.70 海泰新光点评报告：海外布局稳步推进，客户订单有望恢复 ◼ 走势比较 (50%) (36%) (22%) (8%) 6% 20% 24/4/29 24/7/11 24/9/22 24/12/4 25/2/15 25/4/29 ◼ 股票数据 | 总股本/流通(亿股) | 1.21/1.21 | | --- | --- | | 总市值/流通(亿元) | 41.85/41.85 | | 12 个月内最高/最低价 | 49.3/25.48 | | (元) | | 相关研究报告 <<海泰新光点评报告：短期受客户订 单周期影响，业绩恢复可期>>-- 2024-10-31 <<海泰新光点评报告：史赛克产品迭 代影响公司 23 年收入，24 年有望迎 来反转>>--2023-10-29 <<海泰新光点评报告：第二季度订单 波动，未来增长依然可期>>--2023- 09-03 证券分析师：谭紫媚 电话：0755-83688830 E-MAIL：tanzm@tpyzq.com 分析师登记编号：S1190520090001 研究助理 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook for future growth based on revenue recovery and product development [1][2]. Core Views - The company experienced a revenue decline in 2024 due to inventory destocking by major clients, but has shown signs of recovery with revenue growth in Q4 2024 and Q1 2025 [2]. - The company’s medical endoscope product line is expected to recover rapidly as new products are launched and market demand increases [2]. - The company is enhancing its overseas production capabilities to mitigate risks associated with trade policies, which is anticipated to improve supply capacity [2]. - Revenue forecasts for 2025-2027 indicate significant growth, with expected revenues of 5.69 billion, 7.12 billion, and 8.74 billion respectively, reflecting year-on-year growth rates of 28.6%, 25.0%, and 22.8% [2][3]. Summary by Sections Financial Performance - In 2024, the company reported total revenue of 4.43 billion (down 5.90% YoY) and a net profit of 1.35 billion (down 7.11% YoY) [1][3]. - The gross margin for 2024 was 64.51%, showing a slight increase from the previous year [2]. - The company’s net profit margin was stable at 30.20% [2]. Revenue and Profit Forecast - Projected revenues for 2025, 2026, and 2027 are 5.69 billion, 7.12 billion, and 8.74 billion respectively, with corresponding net profits of 1.82 billion, 2.31 billion, and 2.86 billion [2][3]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 1.51, 1.91, and 2.37 respectively [3]. Market and Product Development - The company has launched new products in the U.S. market, including a new 4mm hysteroscope and has made progress in developing other endoscopic products [2]. - The company is expanding its marketing efforts and sales team to enhance brand influence and market penetration [2].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook for future growth, suggesting a favorable investment perspective [1][2]. Core Viewpoints - The company experienced a revenue decline in 2024 due to inventory destocking by major clients, but has shown signs of recovery with revenue growth in Q4 2024 and Q1 2025, achieving revenues of 1.24 billion and 1.47 billion respectively, representing year-on-year increases of 31.59% and 24.86% [2]. - The company’s medical endoscope product line is expected to recover rapidly as new products are launched, including a new 4mm hysteroscope and a 2.9mm cystoscope [2]. - The company maintains stable profitability with a gross margin of 64.51% in 2024, and is expanding its overseas production capabilities to enhance supply capacity [2]. - Revenue projections for 2025-2027 are optimistic, with expected revenues of 5.69 billion, 7.12 billion, and 8.74 billion respectively, reflecting growth rates of 28.6%, 25.0%, and 22.8% [2][3]. Summary by Relevant Sections Financial Performance - In 2024, the company reported total revenue of 4.43 billion (down 5.90% YoY) and a net profit of 1.35 billion (down 7.11% YoY) [1][3]. - The gross margin for 2024 was 64.51%, with a net profit margin of 30.20% [2][3]. - The company’s earnings per share (EPS) for 2025 is projected to be 1.51, with a corresponding price-to-earnings (P/E) ratio of 22.94 [3]. Revenue and Profit Forecast - The forecast for total revenue from 2025 to 2027 is as follows: 5.69 billion in 2025, 7.12 billion in 2026, and 8.74 billion in 2027, with net profits expected to be 1.82 billion, 2.31 billion, and 2.86 billion respectively [2][3]. - The company’s return on equity (ROE) is projected to improve from 10.4% in 2024 to 17.6% in 2027 [3]. Market Position and Strategy - The company is enhancing its brand influence and expanding its sales team to improve market penetration, which has led to increased expenses [2]. - The establishment of production capabilities in the U.S. and Thailand is aimed at mitigating risks associated with trade policies and improving supply chain efficiency [2].